Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amag Pharma

- PMLiVE

Horizon launches $3bn hostile bid for Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

Receptos rejected AZ takeover bid, say sources

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

Perrigo warming to Mylan – at the right price

Perrigo has already rejected three prior bids

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

Teva circling as Perrigo rejects second Mylan offer

Claims latest offer is lower than a recent informal bid

- PMLiVE

Valeant raises offer for Salix; rival Endo bows out

Has increased bid to $173 per share in cash

- PMLiVE

Endo tries to ride out Valeant with $15.7bn bid for Salix

Around $1.2bn more than rival bid

Shire Basingstoke

Shire boosts orphan drug pipeline with Meritage Pharma deal

Firm will also acquire global rights to Meritage’s phase III OBS compound

- PMLiVE

Valeant swoops on Salix with $10bn takeover deal

Firm will also absorb Salix’s $4.6bn debt, adding to its existing $15bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links